203 related articles for article (PubMed ID: 36097870)
1. Structural studies offer a framework for understanding the role of properdin in the alternative pathway and beyond.
Pedersen DV; Lorentzen J; Andersen GR
Immunol Rev; 2023 Jan; 313(1):46-59. PubMed ID: 36097870
[TBL] [Abstract][Full Text] [Related]
2. Functional and structural insight into properdin control of complement alternative pathway amplification.
Pedersen DV; Roumenina L; Jensen RK; Gadeberg TA; Marinozzi C; Picard C; Rybkine T; Thiel S; Sørensen UB; Stover C; Fremeaux-Bacchi V; Andersen GR
EMBO J; 2017 Apr; 36(8):1084-1099. PubMed ID: 28264884
[TBL] [Abstract][Full Text] [Related]
3. Structural Basis for Properdin Oligomerization and Convertase Stimulation in the Human Complement System.
Pedersen DV; Gadeberg TAF; Thomas C; Wang Y; Joram N; Jensen RK; Mazarakis SMM; Revel M; El Sissy C; Petersen SV; Lindorff-Larsen K; Thiel S; Laursen NS; Fremeaux-Bacchi V; Andersen GR
Front Immunol; 2019; 10():2007. PubMed ID: 31507604
[TBL] [Abstract][Full Text] [Related]
4. Recruitment of properdin by bi-specific nanobodies activates the alternative pathway of complement.
Pedersen DV; Rösner T; Hansen AG; Andersen KR; Thiel S; Andersen GR; Valerius T; Laursen NS
Mol Immunol; 2020 Aug; 124():200-210. PubMed ID: 32599335
[TBL] [Abstract][Full Text] [Related]
5. Structure and function of a family of tick-derived complement inhibitors targeting properdin.
Braunger K; Ahn J; Jore MM; Johnson S; Tang TTL; Pedersen DV; Andersen GR; Lea SM
Nat Commun; 2022 Jan; 13(1):317. PubMed ID: 35031611
[TBL] [Abstract][Full Text] [Related]
6. Properdin and factor H production by human dendritic cells modulates their T-cell stimulatory capacity and is regulated by IFN-γ.
Dixon KO; O'Flynn J; Klar-Mohamad N; Daha MR; van Kooten C
Eur J Immunol; 2017 Mar; 47(3):470-480. PubMed ID: 28105653
[TBL] [Abstract][Full Text] [Related]
7. Properdin in complement activation and tissue injury.
Lesher AM; Nilsson B; Song WC
Mol Immunol; 2013 Dec; 56(3):191-8. PubMed ID: 23816404
[TBL] [Abstract][Full Text] [Related]
8. Insights Into Enhanced Complement Activation by Structures of Properdin and Its Complex With the C-Terminal Domain of C3b.
van den Bos RM; Pearce NM; Granneman J; Brondijk THC; Gros P
Front Immunol; 2019; 10():2097. PubMed ID: 31552043
[TBL] [Abstract][Full Text] [Related]
9. The role of properdin in the assembly of the alternative pathway C3 convertases of complement.
Hourcade DE
J Biol Chem; 2006 Jan; 281(4):2128-32. PubMed ID: 16301317
[TBL] [Abstract][Full Text] [Related]
10. Structural basis for the stabilization of the complement alternative pathway C3 convertase by properdin.
Alcorlo M; Tortajada A; Rodríguez de Córdoba S; Llorca O
Proc Natl Acad Sci U S A; 2013 Aug; 110(33):13504-9. PubMed ID: 23901101
[TBL] [Abstract][Full Text] [Related]
11. The interaction of glycoprotein C of herpes simplex virus types 1 and 2 with the alternative complement pathway.
Hung SL; Peng C; Kostavasili I; Friedman HM; Lambris JD; Eisenberg RJ; Cohen GH
Virology; 1994 Sep; 203(2):299-312. PubMed ID: 8053154
[TBL] [Abstract][Full Text] [Related]
12. Properdin binds to late apoptotic and necrotic cells independently of C3b and regulates alternative pathway complement activation.
Xu W; Berger SP; Trouw LA; de Boer HC; Schlagwein N; Mutsaers C; Daha MR; van Kooten C
J Immunol; 2008 Jun; 180(11):7613-21. PubMed ID: 18490764
[TBL] [Abstract][Full Text] [Related]
13. A novel mechanism of complement inhibition unmasked by a tick salivary protein that binds to properdin.
Tyson KR; Elkins C; de Silva AM
J Immunol; 2008 Mar; 180(6):3964-8. PubMed ID: 18322205
[TBL] [Abstract][Full Text] [Related]
14. Analysis of the interaction between properdin and factor B, components of the alternative-pathway C3 convertase of complement.
Farries TC; Lachmann PJ; Harrison RA
Biochem J; 1988 Aug; 253(3):667-75. PubMed ID: 3140783
[TBL] [Abstract][Full Text] [Related]
15. The Role of Properdin in C5 Convertase Activity and C5b-9 Formation in the Complement Alternative Pathway.
Michels MAHM; Maas RJF; van der Velden TJAM; van de Kar NCAJ; van den Heuvel LPWJ; Volokhina EB;
J Immunol; 2021 Nov; 207(10):2465-2472. PubMed ID: 34635587
[TBL] [Abstract][Full Text] [Related]
16. Alternative pathway of complement: recruitment of precursor properdin by the labile C3/C5 convertase and the potentiation of the pathway.
Medicus RG; Götze O; Müller-Eberhard HJ
J Exp Med; 1976 Oct; 144(4):1076-93. PubMed ID: 978134
[TBL] [Abstract][Full Text] [Related]
17. Interaction of C3b(2)--IgG complexes with complement proteins properdin, factor B and factor H: implications for amplification.
Jelezarova E; Vogt A; Lutz HU
Biochem J; 2000 Jul; 349(Pt 1):217-23. PubMed ID: 10861231
[TBL] [Abstract][Full Text] [Related]
18. Analysis of the interactions between properdin, the third component of complement (C3), and its physiological activation products.
Farries TC; Lachmann PJ; Harrison RA
Biochem J; 1988 May; 252(1):47-54. PubMed ID: 3421908
[TBL] [Abstract][Full Text] [Related]
19. Initial properdin binding contributes to alternative pathway activation at the surface of viable and necrotic cells.
van Essen MF; Schlagwein N; van den Hoven EMP; van Gijlswijk-Janssen DJ; Lubbers R; van den Bos RM; van den Born J; Ruben JM; Trouw LA; van Kooten C;
Eur J Immunol; 2022 Apr; 52(4):597-608. PubMed ID: 35092629
[TBL] [Abstract][Full Text] [Related]
20. Factor H-related protein 4 activates complement by serving as a platform for the assembly of alternative pathway C3 convertase via its interaction with C3b protein.
Hebecker M; Józsi M
J Biol Chem; 2012 Jun; 287(23):19528-36. PubMed ID: 22518841
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
